XML 54 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration Agreements - Ipsen Collaboration (Details) $ in Millions	1 Months Ended	3 Months Ended				23 Months Ended
	Feb. 29, 2016 USD ($)	Mar. 30, 2018 USD ($)	Mar. 30, 2018 CAD ($)	Dec. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 29, 2017 USD ($)	Dec. 30, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenues		$ 69,030,000			$ 11,214,000
Net contract asset		$ 31,844,000				$ 9,588,000	$ 9,588,000
Collaborative Arrangement with Ipsen
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment(s)	$ 210,000,000
Milestone payments earned						$ 125,000,000
Additional milestone achievement	199,000,000
Contingent cash receipts (up to)	545,500,000
Research and development arrangement performed for others, reimbursement for costs incurred, percent		35.00%	35.00%
Collaboration period to achieve specified levels of commercial performance		10 years	10 years
Remaining performance obligation		$ 54,000,000
Net contract asset		$ 31,800,000
Collaborative Arrangement with Ipsen | GlaxoSmithKline
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		3.00%	3.00%
Collaborative Arrangement with Ipsen | Initial and Second
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty tier		$ 150,000,000
Collaborative Arrangement with Ipsen | Initial and Second | Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		22.00%	22.00%
Collaborative Arrangement with Ipsen | Initial and Second | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		26.00%	26.00%
Collaborative Arrangement with Ipsen | Initial
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		2.00%	2.00%
Royalty tier		$ 50,000,000	$ 30.0
Collaborative Arrangement with Ipsen | Second
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		12.00%	12.00%
Royalty tier		$ 100,000,000
Collaborative Arrangement with Ipsen | HCC Filing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments earned				$ 10,000,000
Collaborative Arrangement with Ipsen | HCC Acceptance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone achievement	$ 40,000,000
Collaborative Arrangement with Ipsen | EMA Approval - 1L RCC [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone achievement		50,000,000
License revenues		$ 45,800,000

X

- Definition

Collaborative Arrangement, Achievement Levels of Commercial Performance, Period

+ References

No definition available.

+ Details

Name:	exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix:	exel_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Maximum amount eligible for commercial milestones under collaborations agreement.

+ References

No definition available.

+ Details

Name:	exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone Payments Earned

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarned
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent

+ References

No definition available.

+ Details

Name:	exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Tier

+ References

No definition available.

+ Details

Name:	exel_RoyaltyTier
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront Payment(s)

+ References

No definition available.

+ Details

Name:	exel_UpfrontPayments
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: